Oppenheimer Maintains Outperform on Allogene Therapeutics, Lowers Price Target to $13
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Mark Breidenbach maintains an Outperform rating on Allogene Therapeutics (NASDAQ:ALLO) but lowers the price target from $14 to $13.
May 21, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Oppenheimer maintains an Outperform rating on Allogene Therapeutics but lowers the price target from $14 to $13.
The Outperform rating suggests a positive outlook, but the lowered price target indicates some caution. The net impact is likely neutral in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100